此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator

2016年3月16日 更新者:Sandra Carroll、McMaster University

Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator

Sudden cardiac death (SCD) due to a ventricular arrhythmia is a serious cause of cardiovascular death in Canada. The implantable cardioverter defibrillator (ICD) offers high-risk patients a treatment option to reduce the incidence of SCD by delivering an internal shock to restore a normal rhythm, if needed. Definitive evidence has established the effectiveness of the ICD for reducing mortality when used as prophylaxis for SCD (a primary prevention indication). Approximately 3,700 new candidates accrue annually. Practice guidelines define the criteria to determine patient ICD candidacy for primary prevention. However, in addition to SCD risk, ICD candidates may have chronic diseases such as diabetes, renal insufficiency, hypertension, and atrial fibrillation. Thus, balancing the benefits and risks of an ICD can become complex, particularly when competing mortality risks are present. Research has recognized human costs associated with device complications and shocks affecting psychological, health related quality of life (HRQL), and morbidity outcomes. The complexities surrounding the long-term benefits/risks, complications, replacements, and shocks, warrant decision support to prepare patients to make decisions. In Canada, there is no clear framework to support patients' decision-making in the context of ICD treatment options. Decision support, using a decision aid, could moderate treatment related uncertainty and prepare patients to make active, informed, quality decisions.

Objectives: 1) develop a decision aid for ICD candidates to support quality decision-making (informed, deliberate, values-based choices), 2) to evaluate the decision aid, and 3) to determine the feasibility of conducting a trial.

研究概览

研究类型

介入性

注册 (实际的)

82

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Hamilton、Ontario、加拿大、L8P 2X2
        • Hamilton Health Sciences

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Referred for consideration of an ICD(non-CRT)for a primary prevention indication
  • English speaking
  • able to provide informed consent

Exclusion Criteria:

  • unable to understand the decision aid due to a language barrier or visual impairment
  • referred for secondary prevention indication

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配

武器和干预

参与者组/臂
干预/治疗
实验性的:Patient Decision Aid for an ICD (primary prevention, non-CRT)
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
其他名称:
  • 铂DA
无干预:Usual care
The control group will not receive the patient decision aid prior to consultation with the physician.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation.
大体时间:Phase 1-2 (1- year)
Development of the decision aid will be guided by the Ottawa Decision Support Framework (ODSF). Evaluation will include the Decision Aid Acceptability questionnaire comprised of 10 items including comprehensibility, balance of presentation of information, and overall suitability.
Phase 1-2 (1- year)

次要结果测量

结果测量
措施说明
大体时间
Pilot RCT (feasibility)
大体时间:Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
In this feasibility RCT, the feasibility regarding processes (referral and recruitment rates, consent), key to the success of a larger study will be assessed. This includes successful delivery of the decision aid in an efficient manner, the monitoring of resources (budget), and study management (trial coordination, human resources). We will assess the proportion of patients who complete the decision aid, quality questionnaires, and missing data.
Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks)
Decision quality measures
大体时间:Pre consultation (baseline visit)
Decision quality, the extent to which patients' decisions are informed (knowledge) and values based (values, preferences, decisional conflict).
Pre consultation (baseline visit)
Decisional Conflict Scale (DCS)
大体时间:Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
The Decisional Conflict Scale measures a person's perception of the difficulty in making a decision, the extent to which they feel uncertain about treatment options, are knowledgeable about the risks and benefits of options, clear about personal values, and supported in decision making. The scale has good test-retest reliability (Cronbach's alpha coefficients > 0.78) and predictive validity.
Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult)
Sure Test
大体时间:Pre-consultation - baseline visit
The Sure Test is a 4 item decisional conflict screening tool designed for use in clinical practice. The Sure Test is embedded in the decision aid (intervention group).
Pre-consultation - baseline visit
The Center for Epidemiologic Studies Depression Scale (CES-D)
大体时间:Pre consultation - baseline visit (intervention and usual care)
The CES-D has 20 items that measure depressive symptoms. The CES-D has good reliability and validity across community and clinical settings. Associations between depressive symptoms and decision choice will be assessed.
Pre consultation - baseline visit (intervention and usual care)
Preparation for Decision Making scale
大体时间:Post consultation - up to two weeks post baseline visit (intervention group)
The Preparation for Decision Making Scale has 10 categorical items assessing the usefulness of the decision aid in preparing patients to communicate with a health professional.
Post consultation - up to two weeks post baseline visit (intervention group)
The Medical Outcomes Trust Short Form (SF-36v2)
大体时间:Pre consultation - baseline visit (intervention and usual care)
The SF-36 is a reliable and valid generic health related quality of life scale (HRQL) comprised of 36 items. Associations between HRQL and decision choice will be undertaken.
Pre consultation - baseline visit (intervention and usual care)

其他结果措施

结果测量
措施说明
大体时间
Vital status
大体时间:3 months post baseline visit
Alive, deceased
3 months post baseline visit
Implant status
大体时间:Phase 3, three months post baseline visit
Device status - implantable defibrillator/no implantable defibrillator, deferred
Phase 3, three months post baseline visit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sandra L Carroll, PhD、McMaster University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年6月1日

初级完成 (实际的)

2014年9月1日

研究完成 (实际的)

2014年12月1日

研究注册日期

首次提交

2013年5月30日

首先提交符合 QC 标准的

2013年6月11日

首次发布 (估计)

2013年6月12日

研究记录更新

最后更新发布 (估计)

2016年3月17日

上次提交的符合 QC 标准的更新

2016年3月16日

最后验证

2016年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • 12-214
  • 119449 Grant number (其他赠款/资助编号:Canadian Institutes of Health Research)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅